 |
|
|
| |
Patients Above 65 Years of Age Achieved the Same SVR12 as Younger Patients Despite Increased Comorbidities: Findings From a Large Real-World, Multi -Country, Observational Cohort of 12-Week Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir ± Ribavirin
|
| |
| |
Safety and Efficacy of Ledipasvir/Sofosbuvir for the Treatment of Genotype 1 Hepatitis C in Patients Aged 65 Years or Older: A Retrospective Analysis of International Phase 3 Studies - (05/28/15)
Download the PDF here
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Robert Flisiak1, Andreas Maieron2, Michael Kraus3, Vincent Leroy4, Yves Horsmans5, Bela Hunyady6, Suzanne Norris7, Mark Bondin8, Dorota Latarska-Smuga8,
Ana Gabriela Pires dos Santos8, Marisol Marti nez-Tristani8
1Medical University of Bialystok, Bialystok, Poland; 2Elisabethinen Hospital, Linz, Austria; 3University of Wurzburg, Wurzburg, Germany; 4Centre Hospitalier Universitaire de Grenoble, Grenoble, France; 5Cliniques Universitaires Saint-Luc,
Universite Catholique de Louvain, Brussels, Belgium; 6University of Pecs, Pecs and Somogy County Kaposi Mór Teaching Hospital, Kaposvár, Hungary; 7Trinity College, Dublin, Ireland; 8AbbVie Inc., North Chicago, Illinois, United States
|
| |
|
|
|
|
|
